No Data
No Data
Is Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman's Long-Term Stock Picks?
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $84
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $60
Tarsus Pharmaceuticals Provides 2025 Update
Express News | Tarsus Provides 2025 Update: Accelerating the Launch of Xdemvy® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money
No Data